TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02906995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual tablet 4 mg versus Nicorette Lozenge 4mg
Description: * One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~* The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual tablet 4 mg versus Nicorette Lozenge 4mg
Description: * One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~* The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge.
Study: NCT02344056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Having lunch/skipping lunch
Description: Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skipping lunch/having lunch
Description: No lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
Study: NCT02299856

Intervention type: OTHER
Intervention: Cardiac magnetic resonance scan

Intervention type: OTHER
Intervention: Cardiac magnetic resonance scan
Study: NCT01807936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Study: NCT00520403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv every 3 weeks
Study: NCT03219086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined spinal epidural anaesthesia
Description: To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined spinal epidural anaesthesia
Description: To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
Study: NCT01569256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days
Study: NCT00864136

Intervention type: DRUG
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: Women using Mirena for treatment of menorrhagia

Intervention type: DRUG
Intervention: Conventional medical treatment
Description: Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug

Intervention type: DRUG
Intervention: Conventional medical treatment
Description: Women using anti-fibrinolytic agent for treatment of menorrhagia
Study: NCT02957604

Intervention type: DRUG
Intervention: evolocumab
Description: Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.

Intervention type: DRUG
Intervention: evolocumab
Description: Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.
Study: NCT02972749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
Study: NCT03241537

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity modulated radiotherapy
Study: NCT00603382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: GW685698X

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study: NCT00588081

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: QOL
Description: Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
Study: NCT00085098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given by infusion or injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV over 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV over 2 hours

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy 5 days a week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy 5 days a week
Study: NCT01962545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAC alone
Description: Single APT with either aspirin or clopidogrel is discontinued in this arm.
Study: NCT01859052

Intervention type: OTHER
Group type: OTHER
Intervention: Low carbohydrate diet
Description: Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.

Intervention type: OTHER
Group type: OTHER
Intervention: Low carbohydrate diet
Description: Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.

Intervention type: OTHER
Group type: OTHER
Intervention: Low calorie low fat diet
Description: The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet

Intervention type: OTHER
Group type: OTHER
Intervention: Low calorie low fat diet
Description: The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet

Intervention type: OTHER
Group type: OTHER
Intervention: AHA diet recommendations
Description: given information in accordance with the diet and lifestyle recommendations of the American Heart Association.
Study: NCT00597012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial menisectomy
Description: Arthroscopic partial meniscectomy is a surgical procedure that is performed to remove a piece of torn cartilage in the knee joint. Incisions for arthroscopy are quite small, usually about 1 centimeter each. The torn meniscus can be removed using a number of different instruments, including small shavers and scissors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks. This physical therapy regimen will have similar elements and goals as the postoperative intervention offered to Group 1 participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitative physical therapy
Description: This physical therapy is geared specifically toward rehabilitation after APM surgery.
Study: NCT01855282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
Study: NCT02174575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane is administered during anesthesia in Sevoflurane group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane is administered during anesthesia in Desflurane group.
Study: NCT00539032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT03493581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BIOPSY
Description: re-biopsy (primitive tumor or metastasis) specifically for the study, at V2(6 weeks)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood-sampled
Description: * after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),~* after 6 weeks (V2),~* after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),~* - after 12 weeks of treatment (V4- samples for 3rd assessment of PK/PD and other analyses ).~* after 18 weeks (V5- samples for 4th assessment of PK/PD and other analyses,),~* after 24 weeks of treatment (V6-5th assessment of PK/PD and other analyses).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feces samples
Description: If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).
Study: NCT00678470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Alefacept
Description: Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.
Study: NCT03138694

Intervention type: OTHER
Intervention: BHCG monitoring
Description: Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination

Intervention type: OTHER
Intervention: BHCG monitoring
Description: Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination
Study: NCT00006486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxyamidotriazole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxyamidotriazole
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT03212066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Master Mind
Description: Master Mind is a 25-lesson elementary school mindfulness education substance abuse prevention program. Each lesson takes approximately 15 minutes and is designed to be taught by trained teachers every day for 5 weeks.
Study: NCT00520403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Description: 3 MioIU sc escalating to 18 MioIU sc, 3 times weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 0.1mg/kg iv every 3 weeks
Study: NCT02591797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inferior alveolar and lingual nerve block procedure
Description: The needle is inserted laterally to the pterygomandibular pit at its deepest point without noticing any resistance. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution.~The application of anesthesia shall be in accordance with the following guidelines:~1. Topical Anesthetic: Benzocaine 20% (Hurricaine, Clarben Laboratories SA, Madrid, Spain).~2. Dental Needle: short needles (21mm/30g) (Octoplus, Clarben Laboratories SA, Madrid, Spain)~3. anesthetic: lidocaine hydrochloride 2% with epinephrine 1: 100,000 (2% XILOCAINE, Dentsply, Spain).~4. Syringe: carpule syringe-conventional harpoon with suction system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inferior alveolar and lingual nerve block procedure
Description: The needle is inserted laterally to the pterygomandibular pit at its deepest point without noticing any resistance. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution.~The application of anesthesia shall be in accordance with the following guidelines:~1. Topical Anesthetic: Benzocaine 20% (Hurricaine, Clarben Laboratories SA, Madrid, Spain).~2. Dental Needle: short needles (21mm/30g) (Octoplus, Clarben Laboratories SA, Madrid, Spain)~3. anesthetic: lidocaine hydrochloride 2% with epinephrine 1: 100,000 (2% XILOCAINE, Dentsply, Spain).~4. Syringe: carpule syringe-conventional harpoon with suction system.
Study: NCT03858283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Health Care (MBHC) Program
Description: Mindfulness Based Health Care (MBHC) Program for Caregivers of Alzheimer's Disease Patients. The duration of this group was 8 weeks. The program included one session per week, with each session lasting 1 hour and 30 minutes
Study: NCT00055679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study: NCT02532114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT05006846

Intervention type: OTHER
Intervention: Opioid Addiction Recovery Support Software Platform
Description: OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
Study: NCT04239950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl Icosapentate
Description: Ethyl Icosapentate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl Icosapentate
Description: Ethyl Icosapentate
Study: NCT02444975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineral water
Description: 1.5L/day of water on top of the normal fluid intake for 1 year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching program
Description: Coaching program to support increased water intake

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04140240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention group
Description: Parallel Assignment a experimental design with pre test and post test
Study: NCT03146975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.
Study: NCT04521114

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously every week for 13 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leronlimab 700 mg
Description: 700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
Study: NCT02122549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HWD1000
Description: Wearable cardioverter-defibrillator designed for inpatient use
Study: NCT03364478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DML group
Description: The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach.
Study: NCT04521114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leronlimab 350 mg
Description: 350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
Study: NCT03364478

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MLA group
Description: The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach.
Study: NCT01828398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-tDCS + UE robot-assisted therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS + UE robot-assisted therapy
Study: NCT02603861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: LY3154207 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: LY3154207 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: LY3154207 administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Modafinil administered orally.
Study: NCT01543906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLT091001
Description: oral QLT091001 administered once daily for 7 days
Study: NCT01932983

Intervention type: DEVICE
Intervention: Train of four test
Description: TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
Study: NCT01751165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine GSK1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine GSK1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine GSK1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study: NCT05082662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)
Description: One Diclofenac tablet was administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)
Description: One Diclofenac tablet was administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cataflam® 50 coated tablet
Description: One Diclofenac tablet was administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cataflam® 50 coated tablet
Description: One Diclofenac tablet was administered orally.
Study: NCT04095598

Intervention type: DIAGNOSTIC_TEST
Intervention: Comparative Ankle Tomography with Stress Maneuvers
Description: All diagnostic imaging exams and FAAM questionnaire will be applied in a standard way in both groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: Comparative Ankle Tomography with Stress Maneuvers
Description: All diagnostic imaging exams and FAAM questionnaire will be applied in a standard way in both groups.
Study: NCT02982096

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellutome Device
Description: Use of FDA approved Cellutome treatment on burn wounds

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Acellular burn wound management